Acepodia

    OverviewSuggest Edit

    Acepodia is a biotech company developing cell therapies for cancer. It leverages its proprietary bioconjugation ACC (antibody-cell conjugation) platform that links antibodies directly to immune cells, enhancing their tumor-killing ability without the need for genetic manipulation.

    TypePrivate
    Founded2016
    HQTW
    Websiteacepodia.com

    Latest Updates

    Employees (est.) (Sept 2021)37(+3%)
    Cybersecurity ratingAMore

    Key People/Management at Acepodia

    Sonny Hsiao

    Sonny Hsiao

    Chief Executive Officer, President and Co-Founder
    Patrick Y. Yang

    Patrick Y. Yang

    Chairman and Co-Founder
    Joseph S. McCracken

    Joseph S. McCracken

    Senior Vice President of Business Development
    Michael Brock

    Michael Brock

    Chief Strategy Officer
    Thorsten Graef

    Thorsten Graef

    Chief Medical Officer
    Heather Hughes

    Heather Hughes

    Vice President of Clinical Operations
    Show more

    Acepodia Office Locations

    Acepodia has an office in San Mateo
    San Mateo, CA, US
    1825 S Grant St #900
    Show all (2)

    Acepodia Financials and Metrics

    Summary Metrics

    Founding Date

    2016

    Acepodia Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    96/100

    SecurityScorecard logo

    Acepodia Online and Social Media Presence

    Embed Graph

    Acepodia News and Updates

    Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

    Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing with ACE1702, a novel, off-the-shelf natural killer cell therapy

    Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers

    Preclinical data demonstrate potential of off-the-shelf, NK-like gamma-delta T cells in developing cell therapies for the treatment of cancers

    Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer

    Key executive hires strengthen Acepodia’s expanding leadership team and position the company for upcoming growth catalysts Key executive hires strengthen Acepodia’s expanding leadership team and position the company for upcoming growth catalysts

    Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021

    SAN MATEO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny Hsiao, Ph.D., chief executive officer and co-founder of Acepodia, has been invited to speak at the Allogene…

    Acepodia Appoints Jimmy Lai as Chief Financial Officer

    SAN MATEO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointment of Jimmy Lai as chief financial officer. Mr. Lai brings over three decades of financial management a…
    Show more

    Acepodia Frequently Asked Questions

    • When was Acepodia founded?

      Acepodia was founded in 2016.

    • Who are Acepodia key executives?

      Acepodia's key executives are Sonny Hsiao, Patrick Y. Yang and Joseph S. McCracken.

    • How many employees does Acepodia have?

      Acepodia has 37 employees.

    • Who are Acepodia competitors?

      Competitors of Acepodia include TrueBinding, Achilles Therapeutics and EUSA Pharma.

    • Where are Acepodia offices?

      Acepodia has an office in San Mateo.

    • How many offices does Acepodia have?

      Acepodia has 2 offices.